Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionMission Wealth Management, Lp
Latest Disclosed Ownership4,095 shares
Latest Disclosed Value $ 1,828,598
Mission Wealth Management, Lp reports 0.96% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Mission Wealth Management, Lp filed a 13F-HR form disclosing ownership of 4,095 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,828,581 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 4,056 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.96% during the quarter. The current value of the position is $1,829,769 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,095 39 0.96 1,829 -0.54 0.0376
2026-02-05 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,056 89 2.24 1,839 18.35 0.0367
2025-11-04 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,967 -1,742 -30.51 1,554 -38.88 0.0309
2025-08-05 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,709 -1,202 -17.39 2,542 -24.15 0.0544
2025-04-17 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,911 859 14.19 3,350 37.46 0.0822
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,052 -575 -8.68 2,437 -20.90 0.0568
2024-10-31 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,627 815 14.02 3,082 13.11 0.0746
2024-08-05 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,812 -1,995 -25.55 2,724 -16.52 0.0721
2024-04-30 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,807 2,914 59.55 3,263 63.97 0.0858
2024-02-05 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,893 212 4.53 1,991 22.31 0.0646
2023-10-24 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,681 70 1.52 1,628 0.31 0.0606
2023-08-04 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,611 21 0.46 1,623 12.17 0.0613
2023-04-07 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,590 64 1.41 1,446 10.72 0.0606
2023-02-02 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,526 164 3.76 1,307 3.40 0.0625
2022-10-12 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,362 96 2.25 1,263 5.07 0.0669
2022-07-27 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,266 658 18.24 1,202 27.60 0.0632
2022-04-25 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,608 492 15.79 942 37.72 0.0435
2022-02-11 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,116 -55 -1.73 684 18.96 0.0308
2021-11-05 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,171 57 1.83 575 -8.44 0.0293
2021-08-10 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,114 63 2.06 628 -4.27 0.0333
2021-05-10 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,051 490 19.13 656 8.43 0.0381
2021-01-19 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,561 332 14.89 605 -0.33 0.0379
2020-10-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,229 44 2.01 607 -4.26 0.0455
2020-08-03 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,185 52 2.44 634 24.80 0.0547
2020-04-27 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 2,133 -7 -0.33 508 8.32 0.0561
2020-04-10 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,133 -7 508 56,343.6519
2020-01-21 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,140 125 6.20 469 37.54 0.0451
2019-10-16 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,015 -459 -18.55 341 -24.89 0.0364
2019-08-09 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,474 -264 -9.64 454 -9.92 0.0509
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,738 231 9.21 504 21.45 0.0585
2019-02-07 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,507 465 22.77 415 5.33 0.0541
2018-11-01 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,042 0 0.00 394 13.54 0.0519
2018-08-08 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,042 2,042 347 0.0512
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.